

Supplementary Table S1. Data from patients from cohorts included in the study.

Variable	RA-PAZ Cohort (n=161)	RA CLINIC Cohort (n=92)	p-value
Age mean (SD)			
current	64.9 (12.1)	59.9 (13.1)	0.02
at diagnosis	43.7 (13.2)	45.8 (12.3)	0.19
at start bDMARD	52.7 (11.9)	50.6 (12.3)	0.18
Sex (fem) n (%)	133 (82.6)	76 (82.5)	0.5
BMI mean (SD)	26.6 (5.2)	24.6 (6.0)	0.08
Smoking habit n (%)			
smokers	33 (20.5)	25 (27.2)	
ex smokers	42 (25.5)	15 (16.3)	0.18
never smokers	87 (54.0)	50 (54.3)	
Comorbidities n (%)	1 (0-2)	1 (0-2)	0.49
Fibromyalgia n (%)	25 (15.5)	20 (21.7)	0.24
Anxiety-depression n (%)	19 (11.8)	37 (40.2)	<0.01
Previous csDMARDs	2 (2-3)	2 (2-3)	0.78
Erosions n (%)	60 (37.3)	39 (42.3)	0.18
Extraarticular manifestations n (%)	31 (19.3)	12 (13.1)	0.29
Time between diagnosis and starting bDMARD mean (SD)	8.4 (6.1)	5.4 (3.7)	0.01
Current CE n (%)	146 (90.7)	70 (76.1)	<0.01
Current MTX n (%)	122 (75.8)	79 (85.9)	0.07
1st bDMARD n (%)			
TNFi	135 (83.9)	71 (78.0)	0.06
Non TNFi	26 (16.1)	21 (22.0)	
Immunological parameters n (%)			
RF positive	136 (84.5)	77 (83.6)	0.27
ACPA positive	131 (81.4)	75 (81.5)	0.45
SJC mean (SD)	7.8 (4.8)	6.9 (4.2)	0.15
TJC mean (SD)	9.2 (7.0)	7.7 (6.0)	0.07
CRP mean (SD)	5.6 (2.6-17.7)	10.1 (2.5-21.5)	0.22
ESR mean (SD)	32.6 (20.6)	32.7 (26.8)	0.99
VAS mean (SD)	48.4 (22.8)	40.2 (21.3)	0.81
PGA mean (SD)	52.7 (23.0)	64.2 (16.1)	0.01
DAS28 mean (SD)	5.2 (1.2)	5.3 (1.1)	0.93
HAQ mean (SD)	1.2 (0.6)	1.7 (0.5)	0.12

Results are expressed as frequencies and % for categorical variables, mean and standard deviation (SD) or median and interquartile range (IQR) for quantitative variables. *p*-values were calculated using the Chi-square test for categorical variables, and the T-student and U-Man-Whitney tests for continuous variables.

bDMARD: biologic disease-modifying anti-rheumatic drug; BMI: body mass index (kg/m²); csDMARD: conventional synthetic disease modifying antirheumatic drug; CE: corticosteroids; MTX: methotrexate; TNFi: tumour necrosis alpha inhibitor; RF: rheumatoid factor; ACPA: anti citrullinated peptide antibody; TJC: tender joint count; SJC: swollen joint count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; VAS: visual analogue scale-patient; PGA: patient global assessment; DAS28: Disease activity score-28; HAQ: health assessment questionnaire.

Supplementary Table S2. Causes and total of treatment changes in D2T-other RA patients.

-Infusional reactions: n=10
-Infections: n=9
-Cutaneous reactions: n= 13
-Laboratory abnormalities: n= 8
-Lack of adherence n= 12
-Surgical procedures: n= 1
-Intolerance: n=1
-Interstitial lung disease: n=4
-Pregnancy: n=2

Supplementary Table S3. Types and frequencies of extra-articular manifestations at b/tsDMARD initiation.

	D2TRA-inefficacy (n=23)	D2TRA-other (n=3)	Non D2TRA (n=16)
Interstitial lung disease	7	1	5
Secondary Sjögren's syndrome	6	1	7
Rheumatoid nodulosis	7	1	2
Episcleritis	0	0	2
Amyloidosis	2	0	0
Atlantoaxial subluxation	1	0	0
Cutaneous vasculitis	1	0	0